Cargando…

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer

Niclosamide effectively downregulates androgen receptor variants (AR-Vs) for treating enzalutamide and abiraterone-resistant prostate cancer. However, the poor pharmaceutical properties of niclosamide due to its solubility and metabolic instability have limited its clinical utility as a systemic tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Borui, Mottamal, Madhusoodanan, Zhong, Qiu, Bratton, Melyssa, Zhang, Changde, Guo, Shanchun, Hossain, Ahamed, Ma, Peng, Zhang, Qiang, Wang, Guangdi, Payton-Stewart, Florastina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222209/ https://www.ncbi.nlm.nih.gov/pubmed/37242518 http://dx.doi.org/10.3390/ph16050735

Ejemplares similares

SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer
por: Guo, Shanchun, et al.
Publicado: (2019)

From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target
por: Mottamal, Madhusoodanan, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents
por: Zheng, Shilong, et al.
Publicado: (2014)

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
por: Guo, Shanchun, et al.
Publicado: (2018)

Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
por: Liu, Jiawang, et al.
Publicado: (2021)

Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
por: Zhang, Changde, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Synthesis and biological evaluation of niclosamide PROTACs
por: Munoz, Erick, et al.
Publicado: (2022)

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
por: Zhang, Changde, et al.
Publicado: (2017)

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
por: McCutcheon, Stephanie B.
Publicado: (2013)

Modification and Biological Evaluation of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion
por: Zheng, Shilong, et al.
Publicado: (2014)

Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2
por: Li, Rui, et al.
Publicado: (2023)

The chalcone derivative (E)-1-(4-fluorophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one monohydrate
por: Payton-Stewart, Florastina, et al.
Publicado: (2013)

The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis
por: Al-Horani, Rami A., et al.
Publicado: (2019)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma
por: Jordan Montgomery, Emma, et al.
Publicado: (2023)

Alkanediamide-Linked Bisbenzamidines Are Promising Antiparasitic Agents
por: Vanden Eynde, Jean J., et al.
Publicado: (2016)

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
por: Pindiprolu, Sai Kiran S.S., et al.
Publicado: (2020)

Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy
por: Kim, Hyun-Jun, et al.
Publicado: (2021)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Ethacrynic acid is an inhibitor of human factor XIIIa
por: Kar, Srabani, et al.
Publicado: (2022)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

The magic bullet: Niclosamide
por: Jiang, Haowen, et al.
Publicado: (2022)

Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
por: Shamim, Khalida, et al.
Publicado: (2021)

A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer
por: Wang, Lili, et al.
Publicado: (2021)

Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase
por: Al-Horani, Rami A., et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
por: Lopes, Nair, et al.
Publicado: (2021)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

Study on the Synergistic Molluscicidal Effect of Pedunsaponin A and Niclosamide
por: Yang, Chunping, et al.
Publicado: (2022)

Niclosamide: Beyond an antihelminthic drug
por: Chen, Wei, et al.
Publicado: (2018)

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status
por: Zhong, Qiu, et al.
Publicado: (2015)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rruq2cnks8aouf8tdemejhgumc